• Overview
  • Eligibility
  • More info
  • Locations

Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer (NCT00003946)

National Cancer Institute (NCI)
RATIONALE: Hormone therapy may be an effective treatment for endometrial cancer. PURPOSE: Phase II trial to study the effectiveness of danazol in treating patients with advanced or recurrent endometrial cancer.
  • Drug: danazol
    Ages eligible for Study
    all
    Genders eligible for Study
    Female
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Assess the antitumor activity of danazol in patients with advanced or recurrent endometrial cancer. II. Determine the nature and toxicity of danazol in these patients.

    OUTLINE: Patients receive oral danazol 4 times per day for at least 4 weeks. Patients with partial response, complete response, or stable disease continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

    PROJECTED ACCRUAL: A total of 23-56 patients will be accrued for this study within 26 months.

    73 locations

    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    31 July, 1999
    Updated:
    06 June, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!